These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Reitsamer HA; Posey M; Kiel JW Exp Eye Res; 2006 Mar; 82(3):405-15. PubMed ID: 16198336 [TBL] [Abstract][Full Text] [Related]
65. Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants? Kiryazov K; Stefova M; Iotova V Pediatr Emerg Care; 2013 Nov; 29(11):1207-9. PubMed ID: 24196091 [TBL] [Abstract][Full Text] [Related]
66. A medical device/drug delivery system for treatment of glaucoma. Schultz CL; Poling TR; Mint JO Clin Exp Optom; 2009 Jul; 92(4):343-8. PubMed ID: 19389129 [TBL] [Abstract][Full Text] [Related]
67. Failure of naloxone to reverse brimonidine-induced coma in an infant. Sztajnbok J J Pediatr; 2002 Apr; 140(4):485-6; author reply 486. PubMed ID: 12006970 [No Abstract] [Full Text] [Related]
68. [Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow]. Kurysheva NI Vestn Oftalmol; 2019; 135(3):113-120. PubMed ID: 31393455 [TBL] [Abstract][Full Text] [Related]
69. Miotic effect of alphagan P. Faulkner W J Cataract Refract Surg; 2003 Mar; 29(3):423. PubMed ID: 12662989 [No Abstract] [Full Text] [Related]
70. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. Williams GC; Orengo-Nania S; Gross RL J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374 [TBL] [Abstract][Full Text] [Related]
72. A myth of ophthalmic beta-blockers therapy. Kittisupamongkol W Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1721; author reply 1723. PubMed ID: 19693528 [No Abstract] [Full Text] [Related]
73. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? Goldberg I; Moloney G; McCluskey P Med J Aust; 2008 Oct; 189(7):356-7. PubMed ID: 18837675 [TBL] [Abstract][Full Text] [Related]
74. Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma. Frommelt P; Juern A; Siegel D; Holland K; Seefeldt M; Yu J; Uhing M; Wade K; Drolet B Pediatr Dermatol; 2016 Jul; 33(4):405-14. PubMed ID: 27246751 [TBL] [Abstract][Full Text] [Related]
75. [Prospects for neuroprotective glaucoma therapy]. Grehn F Ophthalmologe; 2001 Oct; 98(10):925-8. PubMed ID: 11699312 [No Abstract] [Full Text] [Related]
76. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops. Tomsak RL; Zaret CR; Weidenthal D Br J Ophthalmol; 2003 Jul; 87(7):917. PubMed ID: 12812898 [No Abstract] [Full Text] [Related]
77. A 24-day old with episodic lethargy, hypotonia, and apnea: the eyes have it. Prok L; Hall D Curr Opin Pediatr; 2003 Apr; 15(2):226-8. PubMed ID: 12640283 [No Abstract] [Full Text] [Related]
78. The teardrop sign: a rare dermatological reaction to brimonidine. Scruggs JT; Whiteside-Michel J; Brodsky MC Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417 [No Abstract] [Full Text] [Related]
79. In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea. Piwnica D; Pathak A; Schäfer G; Docherty JR Drugs R D; 2018 Mar; 18(1):87-90. PubMed ID: 29374829 [TBL] [Abstract][Full Text] [Related]
80. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Kent AR; Nussdorf JD; David R; Tyson F; Small D; Fellows D Ophthalmology; 2001 Apr; 108(4):784-7. PubMed ID: 11297498 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]